TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
- Author
- KUPRYJANCZYK, J1 2 ; MADRY, R3 ; PŁUZANSKA, A10 ; RZEPKA-GORSKA, I11 ; URBANSKI, K12 ; ZIELINSKI, J6 ; MARKOWSKA, J3 ; PLISIECKA-HAŁASA, J1 ; BAR, J4 ; KRASZEWSKA, E5 ; ZIOŁKOWSKA, I6 ; TIMOREK, A7 ; STELMACHOW, J7 ; EMERICH, J8 ; JEDRYKA, M9
[1] Department of Molecular Pathology, The Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, ul. Roentgena 5, Warsaw 02-781, Poland
[2] Deportment of Pathology, Medical Academy and Brodnowski Hospital, ul. Kondratowicza 8, Warsaw 03-242, Poland
[3] Chair of Gynecologic Oncology, Medical Academy, ul. Lakowa 1/2, Poznan 61-878, Poland
[4] Department of Immunology, Medical Academy, ul. Dyrekcyjna 5/7, Wroclaw 50-528, Poland
[5] Department of Biostatistics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, ul. Roentgena 5, Warsaw 02-781, Poland
[6] Department of Gynecologic Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, ul. Roentgena 5, Warsaw 02-781, Poland
[7] Department of Obstetrics and Gynecology, Medical Academy and Brodnowski Hospital, ul. Kondratowicza 8, Warsaw 03-242, Poland
[8] Department of Gynecologic Oncology, Medical Academy, ul. Kliniczna 1a, Gdansk 80-402, Poland
[9] Department of Gynecologic Oncology, Medical Academy, ul. Dyrekcyjna 5/7, Wroclaw 50-528, Poland
[10] Department of Gynecologic Oncology, Medical Academy, ul. Paderewskiego 4, Lodz 93-509, Poland
[11] Department of Gynecologic Oncology, Medical Academy, ul. Powstancow Wielkopolskich 72, Szczecin 70-111, Poland
[12] Deportment of Gynecologic Oncology, Institute of Oncology, ul. Garncarska 1 1, Krakow 31-115, Poland - Source
British journal of cancer. 2004, Vol 91, Num 11, pp 1916-1923, 8 p ; ref : 40 ref
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- ERBB2 TP53 ovarian cancer
- Keyword (fr)
- Cancérologie Gène TP53 Tumeur maligne Cancer de l'ovaire Gène erbB2 Appareil génital femelle pathologie Ovaire pathologie
- Keyword (en)
- Cancerology TP53 Gene Malignant tumor Ovary cancer erbB2 Gene Female genital diseases Ovarian diseases
- Keyword (es)
- Cancerología Gen TP53 Tumor maligno Cáncer del ovario Gen erbB2 Aparato genital hembra patología Ovario patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20C Female genital diseases / 002B20C02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16336452
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6602238 
https://dx.doi.org/10.1038/sj.bjc.6602238
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1916\";s:8:\"\u0000*\u0000epage\";s:4:\"1923\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KUPRYJANCZYK\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:8:\"MADRY, R\";i:1;s:13:\"P\u0141UZANSKA, A\";i:2;s:16:\"RZEPKA-GORSKA, I\";i:3;s:11:\"URBANSKI, K\";i:4;s:12:\"ZIELINSKI, J\";i:5;s:12:\"MARKOWSKA, J\";i:6;s:20:\"PLISIECKA-HA\u0141ASA, J\";i:7;s:6:\"BAR, J\";i:8;s:13:\"KRASZEWSKA, E\";i:9;s:14:\"ZIO\u0141KOWSKA, I\";i:10;s:10:\"TIMOREK, A\";i:11;s:13:\"STELMACHOW, J\";i:12;s:10:\"EMERICH, J\";i:13;s:10:\"JEDRYKA, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1916\";s:8:\"\u0000*\u0000epage\";s:4:\"1923\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KUPRYJANCZYK\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:8:\"MADRY, R\";i:1;s:13:\"P\u0141UZANSKA, A\";i:2;s:16:\"RZEPKA-GORSKA, I\";i:3;s:11:\"URBANSKI, K\";i:4;s:12:\"ZIELINSKI, J\";i:5;s:12:\"MARKOWSKA, J\";i:6;s:20:\"PLISIECKA-HA\u0141ASA, J\";i:7;s:6:\"BAR, J\";i:8;s:13:\"KRASZEWSKA, E\";i:9;s:14:\"ZIO\u0141KOWSKA, I\";i:10;s:10:\"TIMOREK, A\";i:11;s:13:\"STELMACHOW, J\";i:12;s:10:\"EMERICH, J\";i:13;s:10:\"JEDRYKA, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1916\";s:8:\"\u0000*\u0000epage\";s:4:\"1923\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KUPRYJANCZYK\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:8:\"MADRY, R\";i:1;s:13:\"P\u0141UZANSKA, A\";i:2;s:16:\"RZEPKA-GORSKA, I\";i:3;s:11:\"URBANSKI, K\";i:4;s:12:\"ZIELINSKI, J\";i:5;s:12:\"MARKOWSKA, J\";i:6;s:20:\"PLISIECKA-HA\u0141ASA, J\";i:7;s:6:\"BAR, J\";i:8;s:13:\"KRASZEWSKA, E\";i:9;s:14:\"ZIO\u0141KOWSKA, I\";i:10;s:10:\"TIMOREK, A\";i:11;s:13:\"STELMACHOW, J\";i:12;s:10:\"EMERICH, J\";i:13;s:10:\"JEDRYKA, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1916\";s:8:\"\u0000*\u0000epage\";s:4:\"1923\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KUPRYJANCZYK\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:8:\"MADRY, R\";i:1;s:13:\"P\u0141UZANSKA, A\";i:2;s:16:\"RZEPKA-GORSKA, I\";i:3;s:11:\"URBANSKI, K\";i:4;s:12:\"ZIELINSKI, J\";i:5;s:12:\"MARKOWSKA, J\";i:6;s:20:\"PLISIECKA-HA\u0141ASA, J\";i:7;s:6:\"BAR, J\";i:8;s:13:\"KRASZEWSKA, E\";i:9;s:14:\"ZIO\u0141KOWSKA, I\";i:10;s:10:\"TIMOREK, A\";i:11;s:13:\"STELMACHOW, J\";i:12;s:10:\"EMERICH, J\";i:13;s:10:\"JEDRYKA, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6602238\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1916\";s:8:\"\u0000*\u0000epage\";s:4:\"1923\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KUPRYJANCZYK\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:8:\"MADRY, R\";i:1;s:13:\"P\u0141UZANSKA, A\";i:2;s:16:\"RZEPKA-GORSKA, I\";i:3;s:11:\"URBANSKI, K\";i:4;s:12:\"ZIELINSKI, J\";i:5;s:12:\"MARKOWSKA, J\";i:6;s:20:\"PLISIECKA-HA\u0141ASA, J\";i:7;s:6:\"BAR, J\";i:8;s:13:\"KRASZEWSKA, E\";i:9;s:14:\"ZIO\u0141KOWSKA, I\";i:10;s:10:\"TIMOREK, A\";i:11;s:13:\"STELMACHOW, J\";i:12;s:10:\"EMERICH, J\";i:13;s:10:\"JEDRYKA, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:82:\"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
